Subscribe to RSS
DOI: 10.1055/a-1954-8532
Antithrombotisches Management nach akutem oder chronischem Koronarsyndrom
Antithrombotic Management in Patients with Acute or Chronic Coronary Syndrome
Zusammenfassung
Nach akutem oder chronischem Koronarsyndrom mit Koronarintervention ist eine antithrombotische Therapie mit dualer Plättchenhemmung erforderlich. Die Intensität und Dauer der Therapie unterscheiden sich je nach Indikation. Für besondere Situationen mit erhöhtem ischämischem Risiko oder erhöhtem Blutungsrisiko liegen Studiendaten vor, auf deren Basis fundierte Entscheidungen zur Intensivierung oder auch zur Deeskalation der Standardtherapie getroffen werden können, um das Nutzen-Risiko-Verhältnis zu optimieren.
Abstract
After an acute coronary syndrome or after coronary intervention for chronic coronary syndrome dual antiplatelet therapy (DAPT) is necessary. Intensity and duration of DAPT are dependent on the respective indication. For clinical scenarios with increased ischemic risk or high bleeding risk clinical trial have been performed. Based on these data decisions for either intensified antithrombotic therapy or de-escalation strategies may be considered to optimise the risk/benefit ratio.
Klinische Studien weisen den Weg zu optimierter antithrombotischer Therapie nach ACS oder elektiver Koronarintervention, insbesondere bei Patienten mit erhöhtem ischämischem oder erhöhtem Blutungsrisiko.
Publication History
Article published online:
05 December 2022
© 2022. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Schomig A, Neumann FJ, Kastrati A. et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-1089 DOI: 10.1056/NEJM199604253341702. (PMID: 8598866)
- 2 Collet JP, Thiele H, Barbato E. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021; 42: 1289-1367 DOI: 10.1093/eurheartj/ehaa575. (PMID: 32860058)
- 3 Yusuf S, Zhao F, Mehta SR. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502 DOI: 10.1056/NEJMoa010746. (PMID: 11519503)
- 4 Silvain J, Lattuca B, Beygui F. et al. Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. Lancet 2020; 396: 1737-1744 DOI: 10.1016/S0140-6736(20)32236-4. (PMID: 33202219)
- 5 Mauri L, Kereiakes DJ, Yeh RW. et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155-2166 DOI: 10.1056/NEJMoa1409312. (PMID: 25399658)
- 6 Bonaca MP, Bhatt DL, Cohen M. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791-1800 DOI: 10.1056/NEJMoa1500857. (PMID: 25773268)
- 7 Bonaca MP, Bhatt DL, Storey RF. et al. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. J Am Coll Cardiol 2016; 67: 2719-2728 DOI: 10.1016/j.jacc.2016.03.524. (PMID: 27046162)
- 8 Eikelboom JW, Connolly SJ, Bosch J. et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017; 377: 1319-1330 DOI: 10.1056/NEJMoa1709118. (PMID: 28844192)
- 9 Mehran R, Baber U, Sharma SK. et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med 2019; 381: 2032-2042 DOI: 10.1056/NEJMoa1908419. (PMID: 31556978)
- 10 Watanabe H, Morimoto T, Natsuaki M. et al. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial. JAMA Cardiol 2022; 7: 407-417 DOI: 10.1001/jamacardio.2021.5244. (PMID: 35234821)
- 11 Valgimigli M, Frigoli E, Heg D. et al. Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. N Engl J Med 2021; 385: 1643-1655 DOI: 10.1056/NEJMoa2108749. (PMID: 34449185)
- 12 Angiolillo DJ, Galli M, Collet JP. et al. Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention 2022; 17: e1371-e1396 DOI: 10.4244/EIJ-D-21-00904. (PMID: 35354550)